TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01021423

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: 15 mg orally once daily on Days 1-21 of every 28-day cycle for a maximum of 2 years or until disease progression, unacceptable toxicity develops or voluntary withdrawal.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo (identical matched capsule) orally once daily on Days 1-21 of every 28-day cycle for a maximum of 2 years or until disease progression, unacceptable toxicity develops or voluntary withdrawal.
Study: NCT01817218

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Platelet Rich Plasma

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Osakidetza protocol
Description: Patients in the control group will be treated following the recommendations of the Ezkerraldea-Enkarterri Health Region, that is, using a moist healing environment (as described in Uso racional de los productos de cura en ambiente húmedo. Plan de formación continuada de Osakidetza, 2011).~The type of material used to treat and dress the wound will be chosen after the assessment of the wound and surrounding skin, type and quantity of exudate and whether there are signs of infection. Wound care will be carried out every 48-72 hours, as is the current usual practice.
Study: NCT01203566

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: LESS appendectomy
Description: See under arms description

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional 3-port laparoscopic appendectomy
Description: See under arms description
Study: NCT00540228

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza Vaccine GSK1247446A - 4 different formulations
Description: Single dose, Intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza Vaccine GSK1247446A - 4 different formulations
Description: Single dose, Intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza Vaccine GSK1247446A - 4 different formulations
Description: Single dose, Intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza Vaccine GSK1247446A - 4 different formulations
Description: Single dose, Intramuscular injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Fluarix™
Description: Single dose, Intramuscular injection
Study: NCT01873625

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT01916733

Intervention type: DRUG
Intervention: standard insulin protocol post-op (continuous IV insulin)
Description: concurrent, matched cohort study of moderate postoperative glucose control in patients undergoing LEB or open AAA repair.Propensity score matching is a statistical method used to reduce the confounding effects of covariates in an observational (non-randomized) study. In practice we will select a number of variables that impact wound infection; age, gender, diabetic and non-diabetic populations, renal insufficiency (defined at creatinine ≥1.8) and indication for surgery (claudication or critical limb ischemia with rest pain or tissue loss or open AAA repair); and chose a group of patients in the Vascular Study Group matched for these variables who have not been treated with an insulin infusion). Consecutive patients undergoing elective open AAA repair or infrainguinal LEB for claudication and critical limb ischemia will be invited to enroll in the study.
Study: NCT01283724

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dienogest (Visanne, BAY86-5258)
Description: Subjects received Dienogest tablet orally at a dosage of 2 mg once daily over a period of 52 weeks.
Study: NCT02277418

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VAVL
Description: Videolaryngoscope

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VAVL
Description: Videolaryngoscope
Study: NCT00781859

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 125 µg Ocriplasmin
Description: 125µg ocriplasmin intravitreal injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo intravitreal injection
Study: NCT02277418

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VAVL
Description: Videolaryngoscope

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VAVL
Description: Videolaryngoscope

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MIL
Description: Direct laryngoscopy

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MIL
Description: Direct laryngoscopy

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MIL
Description: Direct laryngoscopy

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MIL
Description: Direct laryngoscopy
Study: NCT02184520

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TRANSITION

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: REVERE
Study: NCT01234142

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: varenicline free base patch
Description: varenicline transdermal delivery system (12.0 mg payload \[drug amount loaded in each patch\]) will be applied to the skin once daily for 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: varenicline free base patch
Description: varenicline transdermal delivery system (18.0 mg payload \[drug amount loaded in each patch\]) will be applied to the skin once daily for 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo patch
Description: Matched placebo transdermal delivery system will be applied to the skin once daily for 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: varenicline free base patch
Description: varenicline transdermal delivery system (24.0 mg payload \[drug amount loaded in each patch\]) will be applied to the skin once daily for 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo patch
Description: Matched placebo transdermal delivery system will be applied to the skin once daily for 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: varenicline free base patch
Description: 2 varenicline transdermal delivery systems (combined to achieve a maximum drug payload of 36 mg) will be applied to the skin, side by side once daily, for 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo patch
Description: Matched placebo transdermal delivery systems will be applied to the skin, side by side, once daily for 14 days
Study: NCT01883596

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.12% chlorhexidine solution
Description: Bexident® (0.12% chlorhexidine solution)
Study: NCT01249547

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: axitinib
Description: starting dose of 5 mg twice daily for 4 consecutive weeks without interruption.
Study: NCT01883596

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 7.4% alcohol, glycerine, normal saline solution, applied topically, every 8 hrs.
Study: NCT00966550

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Tomato
Description: Tomato with high carb/fat meal

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Non-tomato
Description: Non-tomato with high carb/fat meal
Study: NCT02207413

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influsplit Tetra™ vaccine produced by investigational process (IP)
Description: Influsplit Tetra™ vaccine using a new manufacturing process administered intramuscularly (IM) in the deltoid region of non-dominant arm (Dose 1) in Adults Group and in non-dominant deltoid or left anterolateral thigh (Dose 1) and dominant deltoid or right anterolateral (Dose 2 - unprimed subjects) in 6-35m and 3-17y Groups.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influsplit Tetra™ vaccine produced by investigational process (IP)
Description: Influsplit Tetra™ vaccine using a new manufacturing process administered intramuscularly (IM) in the deltoid region of non-dominant arm (Dose 1) in Adults Group and in non-dominant deltoid or left anterolateral thigh (Dose 1) and dominant deltoid or right anterolateral (Dose 2 - unprimed subjects) in 6-35m and 3-17y Groups.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influsplit Tetra™ vaccine produced by investigational process (IP)
Description: Influsplit Tetra™ vaccine using a new manufacturing process administered intramuscularly (IM) in the deltoid region of non-dominant arm (Dose 1) in Adults Group and in non-dominant deltoid or left anterolateral thigh (Dose 1) and dominant deltoid or right anterolateral (Dose 2 - unprimed subjects) in 6-35m and 3-17y Groups.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Influsplit Tetra™ vaccine produced by licensed process (LP)
Description: Influsplit Tetra™ vaccine using a licensed manufacturing process administered IM in the deltoid region of non-dominant arm (Dose 1) in Adults Group and in non-dominant deltoid or left anterolateral thigh (Dose 1) and dominant deltoid or right anterolateral (Dose 2 - unprimed subjects) in 6-35m and 3-17y Groups.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Influsplit Tetra™ vaccine produced by licensed process (LP)
Description: Influsplit Tetra™ vaccine using a licensed manufacturing process administered IM in the deltoid region of non-dominant arm (Dose 1) in Adults Group and in non-dominant deltoid or left anterolateral thigh (Dose 1) and dominant deltoid or right anterolateral (Dose 2 - unprimed subjects) in 6-35m and 3-17y Groups.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Influsplit Tetra™ vaccine produced by licensed process (LP)
Description: Influsplit Tetra™ vaccine using a licensed manufacturing process administered IM in the deltoid region of non-dominant arm (Dose 1) in Adults Group and in non-dominant deltoid or left anterolateral thigh (Dose 1) and dominant deltoid or right anterolateral (Dose 2 - unprimed subjects) in 6-35m and 3-17y Groups.
Study: NCT00532233

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QAX576
Study: NCT03172026

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maraviroc 300 mg
Description: FDA approved chemokine receptor (CCR5) inhibitor. Maraviroc will be started within two weeks of discharge from inpatient rehabilitation, which most often will occur from 4-6 weeks after stroke onset.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Rehabilitation therapy
Description: All participants will have routine outpatient or home health physical and occupational therapy after inpatient discharge as prescribed by their physicians.~Each group will be contacted weekly by phone to help maintain interest in the trial, count the number of usual care physical and occupational therapy completed, assure use of the assigned medication, ask about possible adverse reactions, and to encourage them to be active. The coordinator will obtain this information and provide the feedback using a standard script and checklist. A unique aspect of this trial is a telerehabilitation component that aims to give feedback to all participants to practice with the affected arm and walk daily.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Rehabilitation therapy
Description: All participants will have routine outpatient or home health physical and occupational therapy after inpatient discharge as prescribed by their physicians.~Each group will be contacted weekly by phone to help maintain interest in the trial, count the number of usual care physical and occupational therapy completed, assure use of the assigned medication, ask about possible adverse reactions, and to encourage them to be active. The coordinator will obtain this information and provide the feedback using a standard script and checklist. A unique aspect of this trial is a telerehabilitation component that aims to give feedback to all participants to practice with the affected arm and walk daily.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo 300 mg
Description: Matched placebo will be started within two weeks of discharge from inpatient rehabilitation, which most often will occur from 4-6 weeks after stroke onset.
Study: NCT04036812

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Superficial cervical plexus block
Description: superficial cervical plexus nerve block will be performed under the guidance of ultrasound

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Control group
Description: ultrasound guidance will be used to determine the location of superficial cervical plexus nerve. The puncture will also be performed by ultrasound guidance, covered with opaque infusion dressing but performed with infusion of 10 ml normal saline.
Study: NCT00365274

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV 750 mg/m\^2 day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin hydrochloride
Description: Given 50 mg/m\^2 IV day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate
Description: Given 1.4 mg/m\^2 IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Description: 100 mg orally daily days 1 - 5

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SGN-30
Description: 12 mg/kg weekly IV over 2 hours once weekly for 3 weeks.
Study: NCT00514371

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tanespimycin
Description: High dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tanespimycin
Description: High dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tanespimycin
Description: High dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Mid dose, and low dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Mid dose, and low dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Mid dose, and low dose
Study: NCT02085304

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Gross total resection and Gliadel(R) wafers implanted
Description: Complete removal of tumor and implant of Gliadel(R) wafers that are small, dime-sized wafers designed to deliver the chemo drug, carmustine, directly into the cavity made when the brain tumor was removed.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Gross total resection and Gliadel(R) wafers implanted
Description: Complete removal of tumor and implant of Gliadel(R) wafers that are small, dime-sized wafers designed to deliver the chemo drug, carmustine, directly into the cavity made when the brain tumor was removed.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: GammaKnife(R) stereotactic Radiosurgery
Description: GammaKnife® (GK) radiosurgery dose of 15 Gy in one fraction to the resection cavity margin

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Standard fractionated radiation therapy
Description: standard fractionated RT of 60 Gy in 30 fractions (over approximately six weeks)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: temozolomide 75 mg/m2 daily for 42 days, will be administered to all patients beginning within 24 hours of GK/RT initiation as is routine clinical care. There will be a one month drug holiday following the 42 days before adjuvant chemotherapy begins. Adjuvant temozolomide administered 5 days monthly at 150-200 mg/m2/day will be administered for 12 months as is routine clinical care.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Temozolomide
Description: temozolomide 75 mg/m2 daily for 42 days, will be administered to all patients beginning within 24 hours of GK/RT initiation as is routine clinical care. There will be a one month drug holiday following the 42 days before adjuvant chemotherapy begins. Adjuvant temozolomide administered 5 days monthly at 150-200 mg/m2/day will be administered for 12 months as is routine clinical care.
Study: NCT02277808

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 500mg Amikacine (Amukin®) diluted in 4mL NaCl (0,9%)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 500mg Amikacine (Amukin®) diluted in 4mL NaCl (0,9%)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Respirgard II

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Isoneb®
Study: NCT04152798

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic hiatal hernia repair with ProGrip™ mesh
Description: Suturing of the right and left diaphragmatic crura using 3 to 4 interrupted nonabsorbable stitches with additional reinforcement of crura repair with ProGrip™ mesh

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic primary posterior crural repair
Description: Posterior cruroraphy will be performed with 3 to 4 interrupted non-absorbable sutures
Study: NCT02105675

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dendritic Cells DCVAC/PCa
Description: DCVAC/PCa is the experimental therapy added on to Docetaxel

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Docetaxel is Standard of Care First Line Chemotherapy
Study: NCT01642108

Intervention type: DRUG
Group type: OTHER
Intervention: Sitagliptin
Description: 50 mg once per day
Study: NCT03704909

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adrenaline
Description: i.v bolus of adrenaline 0.15µg/Kg rescue boluses of adrenaline 0.15µg/Kg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ephedrine
Description: i.v bolus of Ephedrine 0.1mg/Kg rescue boluses of Ephedrine 0.1mg/Kg
Study: NCT00348309

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosiglitazone Extended Release 2mg
Description: Rosiglitazone Extended Release 2mg OD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosiglitazone Extended Release 8mg
Description: Rosiglitazone Extended Release 8mg OD

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Donepezil
Description: Donepezil (At least 6 months of ongoing donepezil therapy for Alzheimer's disease, with stable dosing for at least the last 2 months (and with no intent to change for the duration of the study).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Donepezil
Description: Donepezil (At least 6 months of ongoing donepezil therapy for Alzheimer's disease, with stable dosing for at least the last 2 months (and with no intent to change for the duration of the study).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Donepezil
Description: Donepezil (At least 6 months of ongoing donepezil therapy for Alzheimer's disease, with stable dosing for at least the last 2 months (and with no intent to change for the duration of the study).
Study: NCT03580226

Intervention type: OTHER
Intervention: No intervention
Description: No intervention

Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study: NCT02439034

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paracetamol
Description: Paracetamol 1 g IV then 1 g 3 times a day IV or oral (PO)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paracetamol
Description: Paracetamol 1 g IV then 1 g 3 times a day IV or oral (PO)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketoprofen
Description: Ketoprofen\* 100 mg (IV then PO) : Ketoprofen 100 mg IV 2 times a day or Ketoprofen LP 100 mg PO 2 times a day.
Study: NCT03686475

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Biodentine
Description: pulpotomy for primary molars , clinical and radiographic evaluation at 1,3,6 and 12month

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: MTA pulpotomy
Description: MTA pulpotomy
Study: NCT01303926

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cisplatin pemetrexed
Description: Cisplatin 75 mg / m2 d1 with Pemetrexed 500 mg / m2 d1 every 3 weeks for 6 cycles followed (in responding or stable patients) by Pemetrexed 500 mg / m2 every 3 weeks, until progression or unacceptable toxicity

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: carboplatin paclitaxel bevacizumab
Description: Carboplatin AUC 6 d1 plus Paclitaxel 200 mg/m2 d1 and Bevacizumab 15 mg/kg every 3 weeks for 6 cycles followed in stable or responding patients by Bevacizumab 15 mg/kg every 3 weeks, until progression or unacceptable toxicity
Study: NCT00458653

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dendritic Cell Tumor Fusion
Description: Post-Transplant (Groups A and B): Given under the skin every four weeks for three doses.~Pre-Transplant (Group B): Injected under the skin in upper part of leg or arm prior to stem cell collection for ASCT

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dendritic Cell Tumor Fusion
Description: Post-Transplant (Groups A and B): Given under the skin every four weeks for three doses.~Pre-Transplant (Group B): Injected under the skin in upper part of leg or arm prior to stem cell collection for ASCT
Study: NCT00967811

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formulation E1 of L-PPDS
Description: Control of IOP compared to baseline for Formulation E1 of the experimental dose of Latanoprost-PPDS for 6 weeks or until loss of efficacy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formulation E2 of L-PPDS
Description: Control of IOP compared to baseline for Formulation E2 of experimental dose of Latanoprost-PPDS for 6 weeks or until loss of efficacy.
Study: NCT02609529

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medical Food
Description: Serum-derived bovine immunoglobulin protein isolate will be supplied by EnteraHealth. The product is manufactured in accordance with Good Manufacturing Practice (GMP) and U.S. Food and Drug Administration (FDA) guidelines for medical food ingredients (21 CFR Part 110). Serum-derived bovine immunoglobulin protein isolate (SBI) is generally recognized as safe (GRAS). The FDA has reviewed the safety dossier for SBI as a medical food product.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03244280

Intervention type: DRUG
Group type: OTHER
Intervention: MOB015B
Description: Topical formulation
Study: NCT03187314

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Radiation
Description: RT to 60 Gy, 5 x per week，for 6 weeks. Radiation begun the day after the first dose of SHR-1210

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1210
Description: SHR-1210 (200mg fixed dose every 2 weeks for 5 cycles) will be administered as an intravenous infusion over 60 minutes.
Study: NCT04927858

Intervention type: DRUG
Intervention: Empagliflozin
Description: Empagliflozin